Weekly Recap: Higher ARCALYST guidance and KPL-387 Phase 3 enrollment

What happened

Kiniksa reported third-quarter 2026 revenue of $286 million, up 58% from a year earlier, and net income of $47.3 million. It raised its 2026 ARCALYST sales outlook to $1.045–$1.050 billion, expanded promotion, and continued enrolling and dosing patients in its Phase 3 KPL-387 trial.

Confirmed

Global impact / market context

Higher ARCALYST sales expectations point to stronger anticipated product revenue, while expanded promotion adds sales and marketing costs that could offset some gains. KPL-387 enrollment moves the trial forward, but data are expected only in the second half of 2027, leaving that potential source of future revenue uncertain.

Analyst inference

The recap also reports $568.8 million in quarter-end liquidity, meaning cash and other readily available funds, which gives Kiniksa resources to support promotion and clinical work. JPMorgan raised its price target to $122 from $107 while maintaining an Overweight rating, an analyst view rather than company guidance.

Confirmed

What to watch

1. Watch whether ARCALYST sales meet or exceed the raised 2026 outlook; actual sales below expectations would weaken the revenue contribution implied by the guidance. Analyst inference
2. Track sales and marketing expenses as promotion expands, including the direct-to-consumer campaign, because higher costs could reduce how much revenue growth reaches net income. Analyst inference
3. Kiniksa is enrolling and dosing patients in the Phase 3 KPL-387 trial for recurrent pericarditis, with data expected in the second half of 2027. Confirmed

Evidence

• Original source link unavailable